Triapine
As of the edition of 20 October 2026, Triapine is a small molecule: stopped in 2013; acts on RRM1 and RRM2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 34, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Blood and lymph; Pregnancy and women's health; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 18 | 13 | 5 | 0 |
| Phase 2 | 15 | 13 | 1 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 34 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vion Pharmaceuticals | Lead sponsor of trials | 1998 to now |
| Cancer Therapeutics | Lead sponsor of trials | 2004 to now |